Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells.

Standard

Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. / Schrader, Jörg; Gordon-Walker, Timothy T; Aucott, Rebecca L; van Deemter, Mariëlle; Quaas, Alexander; Walsh, Shaun; Benten, Daniel; Forbes, Stuart J; Wells, Rebecca G; Iredale, John P.

In: HEPATOLOGY, Vol. 53, No. 4, 4, 2011, p. 1192-1205.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Schrader, J, Gordon-Walker, TT, Aucott, RL, van Deemter, M, Quaas, A, Walsh, S, Benten, D, Forbes, SJ, Wells, RG & Iredale, JP 2011, 'Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells.', HEPATOLOGY, vol. 53, no. 4, 4, pp. 1192-1205. <http://www.ncbi.nlm.nih.gov/pubmed/21442631?dopt=Citation>

APA

Schrader, J., Gordon-Walker, T. T., Aucott, R. L., van Deemter, M., Quaas, A., Walsh, S., Benten, D., Forbes, S. J., Wells, R. G., & Iredale, J. P. (2011). Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. HEPATOLOGY, 53(4), 1192-1205. [4]. http://www.ncbi.nlm.nih.gov/pubmed/21442631?dopt=Citation

Vancouver

Schrader J, Gordon-Walker TT, Aucott RL, van Deemter M, Quaas A, Walsh S et al. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. HEPATOLOGY. 2011;53(4):1192-1205. 4.

Bibtex

@article{431250d94d1e44f79a0b6f81d734a293,
title = "Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells.",
abstract = "There is increasing evidence that the physical environment is a critical mediator of tumor behavior. Hepatocellular carcinoma (HCC) develops within an altered biomechanical environment, and increasing matrix stiffness is a strong predictor of HCC development. The aim of this study was to establish whether changes in matrix stiffness, which are characteristic of inflammation and fibrosis, regulate HCC cell proliferation and chemotherapeutic response. Using an in vitro system of {"}mechanically tunable{"} matrix-coated polyacrylamide gels, matrix stiffness was modeled across a pathophysiologically relevant range, corresponding to values encountered in normal and fibrotic livers. Increasing matrix stiffness was found to promote HCC cell proliferation. The proliferative index (assessed by Ki67 staining) of Huh7 and HepG2 cells was 2.7-fold and 12.2-fold higher, respectively, when the cells were cultured on stiff (12 kPa) versus soft (1 kPa) supports. This was associated with stiffness-dependent regulation of basal and hepatocyte growth factor-stimulated mitogenic signaling through extracellular signal-regulated kinase, protein kinase B (PKB/Akt), and signal transducer and activator of transcription 3. ?1-Integrin and focal adhesion kinase were found to modulate stiffness-dependent HCC cell proliferation. Following treatment with cisplatin, we observed reduced apoptosis in HCC cells cultured on stiff versus soft (physiological) supports. Interestingly, however, surviving cells from soft supports had significantly higher clonogenic capacity than surviving cells from a stiff microenvironment. This was associated with enhanced expression of cancer stem cell markers, including clusters of differentiation 44 (CD44), CD133, c-kit, cysteine-X-cysteine receptor 4, octamer-4 (CXCR4), and NANOG. Conclusion: Increasing matrix stiffness promotes proliferation and chemotherapeutic resistance, whereas a soft environment induces reversible cellular dormancy and stem cell characteristics in HCC. This has implications for both the treatment of primary HCC and the prevention of tumor outgrowth from disseminated tumor cells. (HEPATOLOGY 2011;).",
keywords = "Humans, Cell Line, Tumor, Cell Proliferation, Extracellular Signal-Regulated MAP Kinases/metabolism, Proto-Oncogene Proteins c-akt/metabolism, Cisplatin/therapeutic use, Hep G2 Cells, Carcinoma, Hepatocellular/drug therapy/*pathology, Liver Neoplasms/drug therapy/*pathology, STAT3 Transcription Factor/metabolism, Humans, Cell Line, Tumor, Cell Proliferation, Extracellular Signal-Regulated MAP Kinases/metabolism, Proto-Oncogene Proteins c-akt/metabolism, Cisplatin/therapeutic use, Hep G2 Cells, Carcinoma, Hepatocellular/drug therapy/*pathology, Liver Neoplasms/drug therapy/*pathology, STAT3 Transcription Factor/metabolism",
author = "J{\"o}rg Schrader and Gordon-Walker, {Timothy T} and Aucott, {Rebecca L} and {van Deemter}, Mari{\"e}lle and Alexander Quaas and Shaun Walsh and Daniel Benten and Forbes, {Stuart J} and Wells, {Rebecca G} and Iredale, {John P}",
year = "2011",
language = "English",
volume = "53",
pages = "1192--1205",
journal = "HEPATOLOGY",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

RIS

TY - JOUR

T1 - Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells.

AU - Schrader, Jörg

AU - Gordon-Walker, Timothy T

AU - Aucott, Rebecca L

AU - van Deemter, Mariëlle

AU - Quaas, Alexander

AU - Walsh, Shaun

AU - Benten, Daniel

AU - Forbes, Stuart J

AU - Wells, Rebecca G

AU - Iredale, John P

PY - 2011

Y1 - 2011

N2 - There is increasing evidence that the physical environment is a critical mediator of tumor behavior. Hepatocellular carcinoma (HCC) develops within an altered biomechanical environment, and increasing matrix stiffness is a strong predictor of HCC development. The aim of this study was to establish whether changes in matrix stiffness, which are characteristic of inflammation and fibrosis, regulate HCC cell proliferation and chemotherapeutic response. Using an in vitro system of "mechanically tunable" matrix-coated polyacrylamide gels, matrix stiffness was modeled across a pathophysiologically relevant range, corresponding to values encountered in normal and fibrotic livers. Increasing matrix stiffness was found to promote HCC cell proliferation. The proliferative index (assessed by Ki67 staining) of Huh7 and HepG2 cells was 2.7-fold and 12.2-fold higher, respectively, when the cells were cultured on stiff (12 kPa) versus soft (1 kPa) supports. This was associated with stiffness-dependent regulation of basal and hepatocyte growth factor-stimulated mitogenic signaling through extracellular signal-regulated kinase, protein kinase B (PKB/Akt), and signal transducer and activator of transcription 3. ?1-Integrin and focal adhesion kinase were found to modulate stiffness-dependent HCC cell proliferation. Following treatment with cisplatin, we observed reduced apoptosis in HCC cells cultured on stiff versus soft (physiological) supports. Interestingly, however, surviving cells from soft supports had significantly higher clonogenic capacity than surviving cells from a stiff microenvironment. This was associated with enhanced expression of cancer stem cell markers, including clusters of differentiation 44 (CD44), CD133, c-kit, cysteine-X-cysteine receptor 4, octamer-4 (CXCR4), and NANOG. Conclusion: Increasing matrix stiffness promotes proliferation and chemotherapeutic resistance, whereas a soft environment induces reversible cellular dormancy and stem cell characteristics in HCC. This has implications for both the treatment of primary HCC and the prevention of tumor outgrowth from disseminated tumor cells. (HEPATOLOGY 2011;).

AB - There is increasing evidence that the physical environment is a critical mediator of tumor behavior. Hepatocellular carcinoma (HCC) develops within an altered biomechanical environment, and increasing matrix stiffness is a strong predictor of HCC development. The aim of this study was to establish whether changes in matrix stiffness, which are characteristic of inflammation and fibrosis, regulate HCC cell proliferation and chemotherapeutic response. Using an in vitro system of "mechanically tunable" matrix-coated polyacrylamide gels, matrix stiffness was modeled across a pathophysiologically relevant range, corresponding to values encountered in normal and fibrotic livers. Increasing matrix stiffness was found to promote HCC cell proliferation. The proliferative index (assessed by Ki67 staining) of Huh7 and HepG2 cells was 2.7-fold and 12.2-fold higher, respectively, when the cells were cultured on stiff (12 kPa) versus soft (1 kPa) supports. This was associated with stiffness-dependent regulation of basal and hepatocyte growth factor-stimulated mitogenic signaling through extracellular signal-regulated kinase, protein kinase B (PKB/Akt), and signal transducer and activator of transcription 3. ?1-Integrin and focal adhesion kinase were found to modulate stiffness-dependent HCC cell proliferation. Following treatment with cisplatin, we observed reduced apoptosis in HCC cells cultured on stiff versus soft (physiological) supports. Interestingly, however, surviving cells from soft supports had significantly higher clonogenic capacity than surviving cells from a stiff microenvironment. This was associated with enhanced expression of cancer stem cell markers, including clusters of differentiation 44 (CD44), CD133, c-kit, cysteine-X-cysteine receptor 4, octamer-4 (CXCR4), and NANOG. Conclusion: Increasing matrix stiffness promotes proliferation and chemotherapeutic resistance, whereas a soft environment induces reversible cellular dormancy and stem cell characteristics in HCC. This has implications for both the treatment of primary HCC and the prevention of tumor outgrowth from disseminated tumor cells. (HEPATOLOGY 2011;).

KW - Humans

KW - Cell Line, Tumor

KW - Cell Proliferation

KW - Extracellular Signal-Regulated MAP Kinases/metabolism

KW - Proto-Oncogene Proteins c-akt/metabolism

KW - Cisplatin/therapeutic use

KW - Hep G2 Cells

KW - Carcinoma, Hepatocellular/drug therapy/pathology

KW - Liver Neoplasms/drug therapy/pathology

KW - STAT3 Transcription Factor/metabolism

KW - Humans

KW - Cell Line, Tumor

KW - Cell Proliferation

KW - Extracellular Signal-Regulated MAP Kinases/metabolism

KW - Proto-Oncogene Proteins c-akt/metabolism

KW - Cisplatin/therapeutic use

KW - Hep G2 Cells

KW - Carcinoma, Hepatocellular/drug therapy/pathology

KW - Liver Neoplasms/drug therapy/pathology

KW - STAT3 Transcription Factor/metabolism

M3 - SCORING: Journal article

VL - 53

SP - 1192

EP - 1205

JO - HEPATOLOGY

JF - HEPATOLOGY

SN - 0270-9139

IS - 4

M1 - 4

ER -